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Protective immune responses in mice were obtained after oral immunization with rotavirus DNA vaccines encapsulated in
poly(lactide-co-glycolide) (PLG) microparticles. The DNA vaccines used encoded outer capsid proteins VP4 and VP7; proteins
that are the basis for rotavirus serotyping and the generation of virus neutralizing antibodies. One dose of vaccine was given
to BALB/c mice by oral gavage (75 mg DNA/mouse). Rotavirus-specific serum antibodies and intestinal IgA antibodies were
detectable by 6 weeks postimmunization. After challenge with homologous murine rotavirus at 12 weeks postimmunization,
fecal rotavirus antigen was reduced significantly in immunized mice compared with controls. Protective immunity also was
generated by oral delivery of unencapsulated VP 7 DNA vaccine but to a lesser degree. These results demonstrate that the
oral route is effective for generating protective immune responses with rotavirus DNA vaccines targeting neutralization
antigens. © 1999 Academic Press
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Infections with group A rotaviruses cause an esti-
ated 870,000 deaths each year in developing countries
Glass et al., 1996). In the United States, pediatric rota-
irus infections are responsible for 55,000–70,000 hospi-
alizations per year with an estimated cost of more than
1 billion (Glass et al., 1996). Because of the widespread
ature of rotavirus disease, development of vaccines is
onsidered key to its control (Bishop, 1993; Glass et al.,
996). The currently available live, attenuated oral rota-
irus vaccine is promising (Pe´rez-Schael et al., 1997), but
mproved vaccines still are needed, particularly in many
eveloping countries where the need is the greatest
Bishop, 1993; Glass et al., 1996, Keusch and Cash, 1997;
esikari, 1997) but where the live oral vaccine has been
ess effective (Lanata et al., 1996; Linhares et al., 1996).
illed rotavirus vaccines and subunit vaccines may be
ossible (Bishop, 1993), but these types of vaccines do
ot provide endogenously synthesized proteins, and un-
ess adjuvants are used, generally do not elicit cytotoxic
lymphocyte (CTL) responses that may be important in
ontrolling rotavirus infection. Plasmid DNAs encoding
pecific viral proteins permit expression of immunizing
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nfectious Diseases, University of Massachusetts Medical School, 55
ake Avenue North, Worcester, MA 01655. Fax: (508) 856-5981. E-mail:
ohn.E.Herrmann@banyan.ummed.edu.
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148roteins by host cells that take up inoculated DNA. This
esults in the presentation of normally processed pro-
eins to the immune system, which is important for rais-
ng immune responses against the native forms of pro-
eins (Fynan et al., 1993; Webster et al., 1994). Expression
f the immunogen in host cells also results in the im-
unogen having access to class I major histocompati-
ility complex presentation, which is necessary for elic-
ting CD81 CTL responses.
Rotavirus proteins that elicit neutralizing antibodies
re the two outer capsid surface proteins, viral protein
VP) 4 and VP7 (Estes and Cohen, 1989). Before the
evelopment of a serotyping scheme for rotaviruses that
ncluded VP4, VP7 was the sole basis for rotavirus sero-
yping. Rotavirus VP7 is the major neutralization antigen
f the outer capsid and is also the basis on which the
ive, attenuated reassortant rotavirus tetravalent vaccine
s designed (Pe´rez-Schael et al., 1997). Previously we
ound that VP7 and VP4 DNA vaccines given by gene gun
ave protective immunity (Herrmann et al., 1996a,b; Chen
t al., 1997). One correlate of protection against rotavirus
nfection is production of rotavirus-specific intestinal IgA
n vivo (Feng et al., 1994). Thus targeting of rotaviruses to
he gut-associated lymphoid tissue to induce intestinal
gA may be important in the development of rotavirus
accines. Using a method for encapsulation of DNA in
oly(lactide-co-glycolide) (PLG) microparticles (Jones et
l., 1997a,b), we demonstrated (Chen et al., 1998) protec-
ive immunity to rotaviruses with a PLG-encapsulated
NA vaccine encoding the rotavirus antigen VP6. Rota-
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149ORAL ROTAVIRUS DNA VACCINESirus VP6 is located on the first inner capsid and is not
xposed unless the virion is disrupted. It is antigenically
onserved among group A rotaviruses but, unlike anti-
odies to VP4 and VP7, does not elicit antibodies that
eutralize rotavirus in vitro. The results that we obtained
ith a PLG-encapsulated rotavirus VP6 DNA were the
irst to demonstrate protection against an infectious
gent elicited after oral administration of a DNA vaccine.
In this study, we examined the efficacy of a PLG-encap-
ulated rotavirus VP7 DNA vaccine to induce serum and
ucosal antibody responses in adult BALB/c mice and to
rotect against infection after rotavirus challenge. We also
ested a combination of VP7 and VP4 DNA vaccines en-
apsulated in the same PLG preparation to determine
hether the VP4 DNA vaccine would enhance protective
mmune responses. Finally for comparison with PLG-en-
apsulated DNA vaccines, we tested for induction of pro-
ective immune responses to an unencapsulated (‘‘naked’’)
P7 DNA vaccine given orally in saline.
RESULTS
erum antibody production
Inoculated mice were examined for serum total anti-
odies (IgG, IgM, and IgA) every 2 weeks for 12 weeks.
erum antibody titers obtained by the PLG-encapsulated
P7 and VP41VP7 DNA vaccines and the unencapsu-
ated VP7 DNA vaccine are given in Table 1. A 1:100
T
Rotavirus-Specific Serum ELISA Antibodies in BA
Murine VP7 or VP41VP7 DNA Vaccines
Weeks
postimmunization PLG-VP7 PLG-V
0 , 2 (0/5)
6 2.3 6 0.00 (5/5) 2.54 6
8 2.54 6 0.25 (5/5) 2.70 6
10 , 2 (0/5) 2.85 6
Note. 1/log10 ELISA titer, mean values 6 SD (responders/number te
T
Rotavirus-Specific Serum IgA Antibodies in BAL
Murine VP4 or VP41VP7 DNA Vaccines
Weeks
postimmunization EDIM virus PLG-VP41VP7
0 , 0.10 (4/4) , 0.10 (0/6)
6 0.43 6 0.04 (4/4) 0.20 6 0.001 (3/6)
8 Not tested 0.20 6 0.01 (4/6)
10 0.38 6 0.05 (4/4) 0.24 6 0.03 (6/6)Note. Serum IgA (mg/ml), mean values 6 SD (responders/number tested).ilution was the lowest one tested. At the one time point
here antibodies were generated in three of six mice by
he unencapsulated VP7 DNA vaccine, the titer was not
ignificantly different from the titer obtained with the
LG-encapsulated VP7 DNA vaccine at that time point.
erum antibodies in the mice that had received live
otavirus (used as a positive control) had mean 1/en-
yme-linked immunosorbent assay (ELISA) titers (log10)
f 4.1 at Week 10 p.i.
Detection of rotavirus-specific serum IgA was de-
ected in immunized mice at the times shown in Table 2.
ot all mice in each group responded to the DNA vac-
ines. The most consistent responses occurred in mice
hat had been immunized with the PLG-encapsulated
P41VP7 DNA vaccine.
rotection against rotavirus challenge
Immunized mice were challenged with 100 ID50
pizootic diarrhea of infant mice (EDIM) rotavirus at 12
eeks p.i. The results, expressed as ELISA values for
etection of rotavirus antigen shed in stools, are shown
n Fig. 1. Significant reductions in virus antigen shed
ere noted on Days 3–5 for mice that had been immu-
ized with PLG-encapsulated VP7 or VP41VP7 DNA
accines or with EDIM rotavirus. In the same set of
xperiments, mice were immunized with unencapsulated
P7 DNA vaccine to determine the efficacy of encapsu-
ice after Oral Inoculation of PLG-Encapsulated
encapsulated Murine VP7 DNA Vaccine
DNA vaccine
7 VP7 unencapsulated Plasmid control
/6) , 2 (0/6) , 2 (0/5)
/6) , 2 (0/6) , 2 (0/5)
/6) 2.3 6 0.0 (3/6) , 2 (0/5)
/6) , 2 (0/6) , 2 (0/5)
ean values 6 SD are for responders.
ice after Oral Inoculation of PLG-Encapsulated
encapsulated Murine VP7 DNA Vaccine
DNA vaccine
PLG-VP7 VP7 unencapsulated
PLG-plasmid
control
, 0.10 (0/5) , 0.10 (0/6) , 0.10 (0/5)
, 0.10 (0/5) , 0.10 (0/6) , 0.10 (0/5)
, 0.10 (0/5) 0.23 6 0.07 (3/6) , 0.10 (0/5)
0.23 6 0.03 (2/5) 0.20 (1/6) , 0.10 (0/5)ABLE 1
LB/c M
, or Un
P41VP
, 2 (0
0.13 (6
0.16 (6
0.12 (6ABLE 2
B/c M
, or UnMean values 6 SD are for responders.
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150 HERRMANN ET AL.ation on generation of protective immunity. Mice immu-
ized with unencapsulated VP7 DNA vaccine showed
ignificant protection only on Day 5 postchallenge (Fig.
). Data points for the plasmid control shown in Fig. 2
ere the same as those in Fig 1. Compared with the
nencapsulated DNA vaccine, there was significantly
reater reduction of antigen shedding in mice receiving
he PLG-encapsulated DNA vaccine on Days 4 and 5.
otavirus-specific antibodies in stools
Mice were examined for intestinal rotavirus-specific
gA antibodies before and after virus challenge. IgA was
etected in feces of mice that had been immunized with
he PLG-encapsulated VP41VP7 DNA vaccine or EDIM
otavirus at 6, 8, 10, and 12 weeks postimmunization
data not shown). For the DNA vaccine, this suggested
hat rotavirus antigen was expressed and a mucosal
ntibody response had been induced. No rotavirus-spe-
ific IgA was detected in stools of mice immunized with
LG-encapsulated VP7 DNA vaccine, unencapsulated
P7 DNA vaccine, or the PLG-encapsulated control plas-
id DNA.
After virus challenge, in addition to testing for rotavi-
us-specific IgA antibodies in feces, we tested for pos-
ible enhancement of intestinal rotavirus IgG antibodies
ith an IgG-specific ELISA. There were significant differ-
nces (P , 0.01) in fecal IgA and IgG values between the
ice receiving the plasmid DNA control and the mice
hat had received the PLG-encapsulated VP41VP7 DNA
FIG. 1. Protection against EDIM rotavirus challenge in BALB/c mice
rally immunized with PLG-encapsulated VP7 and PLG-encapsulated
P41VP7 DNA vaccines. Virus shedding in feces was determined by
n ELISA for detecting rotavirus antigen and the results reported as A492
alues 6 SD. A positive test is one in which the A492 value is $0.1. There
ere significant differences (P , 0.0002, analysis of variance) in viral
hedding between the mice receiving the PLG-encapsulated plasmids
ncoding VP7 or VP41VP7 and the plasmid control on the days indi-
ated by an asterisk. {, mice inoculated with EDIM virus, n 5 4; ,
ice inoculated with PLG-VP7 DNA vaccine, n 5 5; F, mice inoculated
ith PLG-VP41VP7 DNA vaccine, n 5 6; n, mice inoculated with
ontrol plasmid DNA, n 5 5.accine or live EDIM rotavirus (Figs. 3A and 3B) (P , 0.01 ior EDIM rotavirus immunized mice on Days 1–7 for IgA
nd IgG; P , 0.01 for VP41VP7 DNA vaccine on Days 3
nd 5–7 for IgA and Days 4–7 for IgG). There was no
ignificant enhancement of rotavirus-specific IgA or IgG
n feces of mice that had received the PLG-encapsulated
P7 DNA vaccine or unencapsulated VP7 DNA vaccine.
DISCUSSION
Protective immune responses against rotavirus infec-
ions have been correlated with production of rotavirus-
pecific fecal IgA in vivo in human and porcine studies
s well as in mice (Matson et al., 1993; Feng et al., 1994;
ard, 1996; Yuan et al., 1996; Chen et al., 1998). Thus
nduction of intestinal IgA may be an important correlate
n the development of rotavirus vaccines. Serum IgA has
lso been correlated with protection in mice (Feng et al.,
994; McNeal et al., 1994). In mice immunized by gene
un with VP4, VP6, or VP7 DNA vaccines (Herrmann et
l., 1996a,b; Chen et al., 1997) and in mice orally immu-
ized with a PLG-encapsulated VP6 DNA vaccine (Chen
t al., 1998), we had seen enhanced intestinal IgA re-
ponses after they had been rotavirus challenged. With
he PLG-encapsulated VP6 DNA vaccine, we also had
etected rotavirus-specific intestinal IgA responses be-
ore the mice were challenged. Here we found that oral
mmunization of the PLG-encapsulated VP41VP7 DNA
accine also induced rotavirus-specific intestinal IgA re-
ponses before challenge and enhanced intestinal IgA
esponses to rotavirus after virus challenge. Serum IgA
as detected in mice after immunization with each of the
NA vaccines tested, including the unencapsulated VP7
NA vaccine.
FIG. 2. Protection against EDIM rotavirus challenge in BALB/c mice
rally immunized with unencapsulated (naked) DNA vaccine. Virus
hedding in feces was determined by an ELISA for detecting rotavirus
ntigen and the results reported as A492 values 6 SD. A positive test is
ne in which the A492 value is $0.1. There were significant differences
P , 0.0002, analysis of variance) in viral shedding between the mice
eceiving the plasmid encoding VP7 and the plasmid control on the day
ndicated by an asterisk. {, mice inoculated with EDIM virus, n 5 4; ,
ice inoculated with unencapsulated VP7 DNA vaccine, n 5 6; n, mice
noculated with control plasmid DNA, n 5 5.
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151ORAL ROTAVIRUS DNA VACCINESWe concentrated on the DNA vaccine encoding rota-
irus VP7 because VP7 is the major neutralization anti-
en of the outer capsid and has been the basis for the
esign of the live, attenuated reassortant tetravalent ro-
avirus vaccine (Pe´rez-Schael et al., 1997). For the vac-
ine that contains the plasmids encoding VP4 and VP7
ncapsulated together, we are presuming that some, if
ot most of the DNAs, will be expressed in the same cell,
ut this remains to be shown. There were higher serum
ntibody titers obtained with the PLG-encapsulated
P41VP7 DNA vaccine than with the PLG-encapsulated
P7 DNA vaccine and enhancement of fecal antibody
iters after virus challenge, but there did not appear to be
ny difference in the protection obtained. It remains to be
etermined if the enhanced antibody responses seen
FIG. 3. (A) and (B) ELISA for rotavirus specific IgA (A) or IgG (B) in
tool suspensions from mice that had been orally inoculated with EDIM
irus or DNA vaccines and challenged with EDIM rotavirus. {, mice
noculated with EDIM virus, n 5 4; , PLG-encapsulated VP7 DNA
accine, n 5 5; F, PLG-encapsulated VP41VP7 DNA vaccine, n 5 6; ,
nencapsulated (naked) VP7 DNA vaccine, n 5 6; n, PLG-control
lasmid DNA, n 5 5. The stools were diluted 1:80 (w/v) in PBS. Results
re expressed as A492 values 6 SD. A492 values .0.1 are considered
ositive for IgA and IgG.ere due solely to the addition of VP4 or were obtained pecause the two plasmids were encapsulated in the
ame microparticles. The contribution of antibodies
aised by each of the DNA vaccines to the antibody titers
easured was not established. In future studies we
ope to have assays available for detecting antibodies
pecific for VP4 and VP7. We also will need to determine
ow well a PLG-encapsulated VP4 DNA vaccine will
rotect mice when given alone.
As we found previously with the PLG-encapsulated
P6 DNA vaccine (Chen et al., 1998), more DNA is re-
uired when encapsulated and given orally than is re-
uired for gene gun delivery (Herrmann et al., 1996a,b;
hen et al., 1997) (75 mg compared with two doses of 2.5
g given by gene gun). However, only one inoculation is
equired for PLG-encapsulated DNA vaccines given
rally, whereas gene-gun immunization for rotaviruses
as required multiple inoculations (Herrmann et al.,
996a,b; Chen et al., 1997; Choi et al., 1998). The relative
ffectiveness of the two methods has not been directly
ompared in one experiment, but we expect to do this in
uture studies.
We have not determined the cell or cells targeted by
he encapsulated DNA, but it is likely that similar cells
re involved as those that have been shown to be in-
olved in the uptake of PLG microparticles encapsulating
ntigens (Eldridge et al., 1989; Desai et al., 1996;
’Hagen, 1996), as we previously discussed in detail
Chen et al., 1998). PLG microparticles are not selectively
argeted to M cells, but nonspecific binding to M cells
nd subsequent transcytosis has been shown in rabbits
Jepsom et al., 1993, 1996).
In addition to binding of PLG by M cells, it is assumed
hat encapsulation protects the DNA from degradation by
ucleases. It had been shown in other studies that naked
NA encoding luciferase did induce immune responses,
ut PLG encapsulation enhanced the responses (Jones
t al., 1997a), and CTL responses to naked DNA encod-
ng measles antigen given orally generated CTL re-
ponses to that antigen (Etchart et al., 1996). We obtained
artial protection after oral administration of naked VP7
NA vaccine, but the consistency of the antibody re-
ponses measured and the protection obtained were
reater with the PLG-encapsulated VP7 DNA vaccine.
e will be testing unencapsulated VP4 and VP41VP7
NA vaccines in future studies.
Adult mice (mice older than 2 weeks) do not develop
iarrhea after rotavirus infection. Because of this, protec-
ive immunity in the adult mice used was measured by
eduction of rotavirus antigen shed after challenge. How-
ver, because rotavirus infection can occur in the ab-
ence of disease, protection against rotavirus infection
ay be as stringent or a more stringent measure of
rotection than protection from disease (O’Neal et al.,
997).
It has been suggested that DNA might make a third
eneration of rotavirus vaccines (Vesikari, 1997) and may
rovide more effective rotavirus vaccines in the future.
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152 HERRMANN ET AL.NA vaccines encapsulated in PLG microparticles com-
ine the ease of administration by the oral route with
argeting of mucosal tissues. The results that we ob-
ained extend the results we previously obtained with a
LG-encapsulated rotavirus VP6 DNA vaccine (Chen et
l., 1998) and demonstrate the potential for development
f PLG-encapsulated rotavirus DNA vaccines based on
eutralization antigens.
MATERIALS AND METHODS
irus and mice
Epizootic diarrhea of infant mice (EDIM) rotavirus
train EW (P10[16], G3) was used for preparation of
DNA encoding VP4 and VP7 and for virus challenge of
ice. The virus challenge stock was prepared by pas-
aging virus from intestinal homogenates of EDIM rota-
irus-infected infant mice in adult mice. Virus for chal-
enge was stool samples diluted in saline. The ID50 of the
tock virus was the 50% shedding dose as determined by
etection of rotavirus antigen shed in feces of infected
ice. The mice used for vaccine studies were obtained
rom rotavirus-free colonies (Taconic, Germantown, NY)
t 6–8 weeks of age and were housed in plastic mi-
roisolater cages before and after immunization. The
odel developed by Ward et al. (1990) for BALB/c mice
as used to measure protective immunity. In this model,
he endpoint is infection rather than illness, because
llness generally is limited to infant mice aged #15 days.
he adult mouse ($6 weeks) becomes infected and
heds virus in feces for ;1 week postinfection. Protec-
ion after virus challenge was defined as significant re-
uction of rotavirus antigen shed in feces during a 7-day
eriod.
NA vaccines
The plasmids encoding rotavirus VP4 or VP7 were
repared by insertion of murine rotavirus VP4 or VP7 into
he pCMV intron A TPA expression vector provided to us
y Dr. J. Mullins, University of Washington (plasmid
W4303) (Yasatumi et al., 1996). This vector uses se-
uences from the CMV immediate early promoter to
rive transcription and sequences from bovine growth
ormone genes to provide polyadenylation signals. To
repare VP4 (GenBank Accession No. MRU08429) DNA
accine by blunt end ligation and VP7 (GenBank Acces-
ion No. MRU08430) DNA vaccine by cohesive end liga-
ion, the TPA leader sequence was removed by treatment
ith restriction endonucleases HindIII and BamHI. For
nsertion of VP7, the HindIII site was changed to a BamHI
ite. Newly constructed plasmids in the correct orienta-
ion were identified by restriction endonuclease diges-
ion. Expression of rotavirus VP4 or VP7 in transfected
OS cells was confirmed by indirect immunofluorescent
taining with monoclonal antibodies to VP4 or VP7. The
ontrol DNA vaccine was plasmid JW4303 without the
iral cDNA insert. Encapsulation of DNA vaccines
Plasmid DNAs were encapsulated in poly (lactide-co-
lycolide) (PLG) microparticles by the solvent extraction
echnique as previously described (Jones et al., 1996,
997a,b). In brief, the DNA was emulsified with PLG
issolved in dichloromethane, and this water-in-oil emul-
ion was emulsified with aqueous polyvinyl alcohol (an
mulsion stabilizer) to form a (water-in-oil)-in-water dou-
le emulsion. This double emulsion was added to a large
uantity of water to dissipate the dichloromethane,
hich resulted in the microdroplets hardening to form
icroparticles. The microparticles were harvested by
entrifugation, washed several times to remove the poly-
inyl alcohol and residual solvent, and lyophilized. PLG
ncapsulation of the VP41VP7 DNA vaccine was pre-
ared by mixing the two plasmids in equal proportions
efore encapsulation. The microparticles containing
NA had a mean diameter of 0.5 mm. To test for DNA
ontent, the microparticles were dissolved in 0.1 M
aOH at 100°C for 10 min. The A260 was measured and
he amount of DNA calculated from a standard curve.
ncorporation of DNA into microparticles was 1.52 mg
NA per milligram PLG for the VP7 DNA vaccine, 2.1 mg
NA per milligram PLG for the VP41VP7 DNA vaccine,
nd 1.75 mg DNA per milligram PLG for the plasmid
ontrol.
mmunization of mice
BALB/c mice were inoculated orally (by gavage) with
LG-encapsulated plasmid DNA encoding murine rota-
irus VP7, VP4 1 VP7, or control plasmid DNA (n 5 6
ice for each inoculation). The mice were fasted 4–5 h
efore inoculation. The microparticles were suspended
n a solution of 0.1 M sodium bicarbonate in distilled
ater, pH 8.5, and given at 0.5 ml per mouse. The DNA
ose administered was ;75 mg DNA per mouse. In one
et of mice (n 5 6), unencapsulated VP7 DNA vaccine
uspended in saline was inoculated orally (by gavage) at
5 mg DNA per mouse. Another group of mice was
mmunized with live EDIM rotavirus 12 weeks before
hallenge for use as a positive control.
ntigen and antibody tests
For monitoring viral antigen shedding in mouse feces,
e used a commercial monoclonal antibody-based en-
yme-linked immunosorbent assay (ELISA) in microtiter
lates (Rotaclone, Meridian Diagnostics, Cincinnati, OH)
s described by the manufacturer. For evaluating rotavi-
us-specific serum antibody responses, an indirect
LISA for total antibody (IgG, IgM, and IgA) (Feng et al.,
994; Herrmann et al., 1996a,b; Chen et al., 1997), was
sed with EDIM rotavirus-coated wells. Peroxidase-la-
eled anti IgA (goat anti-mouse IgA, Southern Biotech-
ology Associates, Inc., Birmingham, AL) was used in the
LISA to determine rotavirus-specific serum IgA levels.
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153ORAL ROTAVIRUS DNA VACCINESntestinal IgA and IgG antibodies to EDIM virus were
etermined by use of IgA- or IgG-specific peroxidase-
abeled antiglobulin in an indirect ELISA (Feng et al.,
994; Herrmann et al., 1996a,b; Chen et al., 1997). Five
ercent (wt/vol) stool suspensions in 0.01 M phosphate
uffered saline, pH 7.1, were further diluted 1:4 (final
ilution of 1:80) for assay of fecal IgA.
tatistical analyses
Statistical analyses were performed using a nonpara-
etric Wilcoxon 2-sample test for ranked data and anal-
sis of variance and the Student-Newman–Keuls test for
ultiple comparison of the differences among experi-
ental groups.
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